Circulating pancreatic polypeptide concentrations predict visceral and liver fat content

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 1048-1052

  Sam, Amir H ^a   Sleeth, Michelle L ^b   Thomas, E Louise ^c   Ismail, Nurhafzan A ^b   Daud, Norlida Mat ^b,d   Chambers, Edward ^b   Shojaee Moradie, Fariba ^e   Umpleby, Margot ^e   Goldstone, Anthony P ^b   Le Roux, Carel W ^a,f   Bech, Paul ^a,g   Busbridge, Mark ^g   Laurie, Rosemary ^a   Cuthbertson, Daniel J ^h   Buckley, Adam ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a   Frost, Gary S ^b   Bell, Jimmy D ^c   Murphy, Kevin G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WESTMINSTER   (United Kingdom)

^d UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

^g IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PANCREAS POLYPEPTIDE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FAT CONTENT; FATTY LIVER; FEMALE; GENDER; HOMEOSTATIC MODEL ASSESSMENT 2 INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; INTRAHEPATOCELLULAR LIPID CONTENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PANCREAS FUNCTION TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WHOLE BODY MRI; BLOOD; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLISM; OVERWEIGHT; PROGNOSIS;

BODY FAT DISTRIBUTION; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIVER; MALE; OBESITY; OVERWEIGHT; PANCREATIC POLYPEPTIDE; PROGNOSIS;

EID: 84924935439     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3450     Document Type: Article

References (20)

1. Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation. 2011;124:e837-e841.
2. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635-643.
3. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48.
4. Thomas EL, Parkinson JR, Frost GS, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring). 2012;20:76-87.
5. Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides. 2007;28:459-463.
6. Schwartz TW. Pancreatic polypeptide: A hormone under vagal control. Gastroenterology. 1983;85:1411-1425.
7. Tong J, Utzschneider KM, Carr DB, et al. Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects. Diabetologia. 2007;50:439-442.
8. Sive AA, Vinik AI, van Tonder SV. Pancreatic polypeptide (PP) responses to oral and intravenous glucose in man. Am J Gastroenterol. 1979;71:183-185.
9. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430-15435.
10. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz P. Proceedings: Radioimmunoassay of a new gut hormone-human pancreatic polypeptide. Gut. 1976;17:393-394.
11. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2192.
12. Thomas EL, Saeed N, Hajnal JV, et al. Magnetic resonance imaging of total body fat. J Appl Physiol (1985). 1998;85:1778-1785.
13. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: A magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut. 2005;54:122-127.
14. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40:1387-1395.
15. Smith JD, Borel AL, Nazare JA, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: Results from the INSPIREMEIAA study. J Clin Endocrinol Metab. 2012;97:1517-1525.
16. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609-1616.
17. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1093-1097.
18. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584.
19. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of nonalcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-872.
20. Schwartz TW, Holst JJ, Fahrenkrug J, et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest. 1978;61:781-789.